上海美农生物科技股份有限公司 第五届董事会第十五次会议决议公告 证券代码：301156 证券简称：美农生物 公告编号：2025-060 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海美农生物科技股份有限公司（以下简称"公司"）第五届董事会第十五 次会议通知于 2025 年 10 月 21 日以通讯方式发出。本次会议于 2025 年 10 月 27 日在公司会议室以现场会议与通讯会议相结合的方式召开。本次会议应出席董事 7 人，实际出席董事 7 人。其中，董事熊英、肖伟伟、向川、邓纲、刘军岭通过 通讯方式出席会议。本次会议由董事长洪伟先生召集并主持，公司高级管理人员 列席本次会议。本次董事会会议的召集、召开和表决程序符合《公司法》《公司 章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于公司〈2025 年第三季度报告〉的议案》 经审议，董事会认为：公司《2025 年第三季度报告》真实、准确、完整地 反映了公司 2025 年第三季度的财务状况和经营成果，不存在虚假记载、误导性 陈述或重大遗漏。 本议案在提 ...

证券代码：301156 证券简称：美农生物 公告编号：2025-061 上海美农生物科技股份有限公司 关于 2025 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 董事会拟定 2025 年中期利润分配方案为：以实施权益分派股权登记日登记 的公司总股本为基数，向全体股东每 10 股派发现金红利 1.00 元（含税），不送 红股，不以资本公积金转增股本。以本公告披露日的公司总股本 140,784,675 股计算，合计派发现金 14,078,467.50 元，公司剩余未分配利润结转以后分配。 上海美农生物科技股份有限公司（以下简称"公司"）2025 年 10 月 27 日 召开的第五届董事会第十五次会议，审议通过了《关于 2025 年中期利润分配方 案的议案》，该议案尚需提交公司股东会审议，现将相关情况公告如下： 一、相关审议程序及意见 （一）独立董事专门会议审核意见 公司第五届董事会独立董事专门会议 2025 年第四次会议审议通过了《关于 2025 年中期利润分配方案的议案》，独立董事认为：公司 2025 年中期利润分配 方 ...

Core Insights - The company reported third-quarter revenue of 154 million, representing a year-over-year increase of 16.22% [1] - Net profit for the third quarter was 17.39 million, showing a year-over-year growth of 49.67% [1] - For the first three quarters, total revenue reached 390 million, reflecting a year-over-year increase of 14.68% [1] - Net profit for the first three quarters amounted to 40.92 million, with a year-over-year growth of 29.44% [1]

证券代码：301156 证券简称：美农生物 公告编号：2025-058 上海美农生物科技股份有限公司 关于控股股东、实际控制人的一致行动人 提前终止减持计划的公告 公司股东上海全裕智合管理咨询事务所（有限合伙）保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 3、股东减持股份情况 证券代码：301156 证券简称：美农生物 公告编号：2025-058 上海美农生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日披露了《关于控股股东、实际控制人的一致行动人股份减持计划的预披露公告》 （公告编号：2025-048），上海全裕智合管理咨询事务所（有限合伙）（以下简 称"全裕"）持有公司股份 10,393,201 股，计划在减持计划公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减持其持有的公司股份不超过 1,407,846 股（即不超过公司总股本的 1%）。 公司近日收到股东全裕出具的《关于提前终止减持上海美农生物科技股份有 限公司股份的告知函》，截至本公告披露日，全裕通过集中竞 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Meino Biological, including stock price movement and trading volume [1] - On October 13, Meino Biological's stock rose by 2.70%, with a trading volume of 253 million yuan, and a net financing purchase of 6.27 million yuan [1] - The total financing and securities balance for Meino Biological reached 54.91 million yuan, accounting for 3.39% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Meino Biological increased to 12,700, a rise of 74.14%, while the average circulating shares per person decreased by 33.43% [2] - For the first half of 2025, Meino Biological reported a revenue of 236 million yuan, representing a year-on-year growth of 13.69%, and a net profit attributable to shareholders of 23.53 million yuan, up 17.68% year-on-year [2] Group 3 - Since its A-share listing, Meino Biological has distributed a total of 154 million yuan in dividends [3] - As of June 30, 2025, the seventh largest circulating shareholder of Meino Biological is the Guotai Zhongzheng Livestock Breeding ETF, holding 821,400 shares as a new shareholder [3]

Group 1 - The pet economy concept stocks in the A-share market are experiencing a counter-trend rise, with notable increases in stock prices for several companies [1] - Yiyi Co., Ltd. reached a 10% limit up, while Babi Food increased by 6%, and other companies like Yuanfei Pet and Jieya Co. saw rises exceeding 5% [1] - The overall trend indicates a positive sentiment in the pet industry, as reflected by the MACD golden cross signal formation [1] Group 2 - Yiyi Co., Ltd. has a total market value of 6.346 billion and a year-to-date increase of 113.23% [2] - Babi Food has a market capitalization of 5.776 billion with a year-to-date increase of 45.81% [2] - Yuanfei Pet has a market value of 4.620 billion and a year-to-date increase of 54.05% [2] - Jieya Co. has a market capitalization of 3.847 billion and a year-to-date increase of 87.03% [2] - Petty Co. has a market value of 4.693 billion with a year-to-date increase of 8.49% [2] - Other companies like Biological Co. and Lusi Co. also showed significant increases in their stock prices and market values [2]

Group 1 - The A-share market's pet economy concept stocks are experiencing a counter-trend rise, indicating strong investor interest in this sector [1] - Yiyi Co., Ltd. has reached a 10% daily limit increase, showcasing significant market confidence [1] - Other notable performers include Babi Foods with a 6% increase, and Yuanfei Pet, Jeya Co., Ltd. with over 5% gains [1] Group 2 - Peti Co., Ltd., Bio Co., Ltd., Lusi Co., Ltd., and Shuangta Foods have all seen increases of over 4%, reflecting a broad positive sentiment in the pet industry [1] - Meino Biological, Haoyue Nursing, Ruipu Biological, and Chuangyuan Co., Ltd. have also reported gains exceeding 3%, further indicating the sector's resilience [1]

Core Insights - The company is currently focused on the research, production, and sales of feed additives and enzymatic protein feed raw materials, and is not involved in the development, production, or sales of vaccines [2] Group 1 - The company plans to continuously iterate and upgrade existing products based on industrial policies, industry development trends, and market and customer demands [2] - The company aims to develop efficient, safe, and environmentally friendly feed additives and enzymatic protein feed raw materials and their application solutions [2]

Core Viewpoint - The company, Meino Biological (301156.SZ), is currently focused on the research, production, and sales of feed additives and hydrolyzed protein feed materials, and does not plan to develop vaccines at this time [2]. Group 1: Company Focus - The company is concentrating on the development of feed additives and hydrolyzed protein feed materials [2]. - There is no current involvement in the research, production, or sales of vaccines [2]. - The company aims to continuously upgrade existing products based on industry policies, market trends, and customer needs [2]. Group 2: Future Development - The company is committed to researching and developing efficient, safe, and environmentally friendly feed additives and hydrolyzed protein feed materials and their application solutions [2].

Core Viewpoint - The company is currently focused on the research, production, and sales of feed additives and enzymatic protein feed raw materials, and is not involved in the research, production, or sales of vaccines [1] Group 1 - The company will continue to iterate and upgrade existing products based on industrial policies, industry development trends, market, and customer needs [1] - The company aims to develop efficient, safe, and environmentally friendly feed additives and enzymatic protein feed raw materials and their application solutions [1]